Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21600746 | 0.90 | HDAC1 (0.52) | MAPTGAAKDM4EMAPK1HTT | |
| SCHEMBL30045005 | 0.89 | ALDH1A1 (0.43) | MAPTGAAKDM4EMAPK1HTT | |
| SCHEMBL25139796 | 0.89 | ALDH1A1 (0.43) | MAPTGAAKDM4EMAPK1HTT | |
| SCHEMBL21600862 | 0.89 | HDAC2 (0.42) | MAPTGAAKDM4EMAPK1HTT | |
| SCHEMBL16071545 | 0.89 | HDAC1 (0.51) | MAPTGAAKDM4EMAPK1HTT | |
| SCHEMBL21600816 | 0.88 | CASP6 (0.49) | MAPTMAPK1HDAC3HDAC2HDAC1 | |
| SCHEMBL30002368 | 0.88 | CASP6 (0.49) | MAPTMAPK1HDAC3HDAC2HDAC1 | |
| SCHEMBL23606833 | 0.87 | AAK1 (0.43) | MAPTGAAKDM4EMAPK1HTT | |
| SCHEMBL30043568 | 0.87 | AAK1 (0.43) | MAPTGAAKDM4EMAPK1HTT | |
| SCHEMBL16071685 | 0.87 | GAA (0.51) | MAPTGAAKDM4EHDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582654-B2 | Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4083021-B1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2025-07-02 | — | — | EP | disclosed |
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
| CN-112313207-B | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | 北京赛特明强医药科技有限公司 | 2023-02-14 | — | — | CN | disclosed |
| EP-4083021-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021129561-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
| EP-2877177-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | Pierre Fabre Médicament (FR) | 2015-06-03 | — | — | EP | disclosed |
| US-8883821-B2 | Substituted pyrazolo[3,4-b]pyridines as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2014-11-11 | — | — | US | disclosed |
| WO-2014016433-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PIERRE FABRE MEDICAMENT (FR) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014016434-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | PIERRE FABRE MEDICAMENT (FR) | 2014-01-30 | — | — | WO | disclosed |
| EP-2689778-A1 | Derivatives of azaindoles or diazaindoles for treating pain | PIERRE FABRE MEDICAMENT (FR) | 2014-01-29 | — | — | EP | disclosed |
| EP-2689779-A1 | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk | PIERRE FABRE MEDICAMENT (FR) | 2014-01-29 | — | — | EP | disclosed |
| EP-2668184-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | Pierre Fabre Medicament (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-20130172360-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2013-04-04 | — | — | US | disclosed |
| WO-2012101239-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | MAPT 3209/4885GAA 572/4885KDM4E 1362/4885 |
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | FGFR4, FGFR1, WEE1 | MAPT 3251/4885GAA 3528/4885KDM4E 886/4885 |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | MAP2K5, MAP2K2, MAP2K3 | MAPT 5/4885GAA 1471/4885KDM4E 1447/4885 |
| US-20130172360-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | MAP2K5, MAP2K2, MAP2K3 | MAPT 5/4885GAA 1471/4885KDM4E 1447/4885 |
| US-12582654-B2 | Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof | FGFR4, FGFR3, FGFR1 | MAPT 3543/4885GAA 4446/4885KDM4E 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.